Fennec Finds Ex-US Commercial Partner For Pedmark In UK’s Norgine

 
• By Joseph Haas

Norgine will market Pedmark, indicated to reduce risk of chemotherapy-related hearing loss in pediatric cancer, in the EU and UK. It will seek additional approvals in Australia and New Zealand.

Norgine will market Fennec's hearing loss drug in the EU and elsewhere

More from Deals

More from Business